Abstract: Objective The aim of this study was to investigate the short-term efficacy and tolerance of sofosbuvir/velpatasvir and ribavirin combination in the treatment of hepatitis C patients with genotype 2 or 3 infection. Methods 58 patients with chronic hepatitis C (CHC) and genotype 2 or 3 infection were enrolled in our hospitals from June 2018 through April 2019, and were randomly divided into two groups, 29 in each group. The patients in control group were treated with ribavirin combined with interferonα-2b, and those in the observation group were treated withsofosbuvir/velpatasvir and ribavirin combination. The regimen in the two groups lasted for three months. Serum HCV RNA was detected by RT-PCR, and the viral genotypes was determined by genetic chip sequencing. Results The rapid viralogical response and early viralogical response rates in the observation group were 72.4% and 89.7%, significantly higher than 44.8% and 65.5%(P＜0.05) in the control; at the end of four week treatment, the white blood cell counts in the observation was(5.8±2.1)×10⁹/L, significantly higher than 【(3.7±1.9)×10⁹/L, P＜0.05】 in the control group; at the end of 12 week treatment, the white blood cell count andplatelet count were(3.4±0.4)×10⁹/L and (99.60±24.2)×10⁹/L, both significantly higher than【(2.9±0.9)×10⁹/L and (82.01±14.8)×10⁹/L, respectively, P＜0.05】 in the control group; there was no significantly differences as compared to the side effects in the two groups, and no discontinuation because of severe untoward reactions happened in the two groups. Conclusion The application of sofosbuvir/velpatasvir and bibavirin combination therapyin the treatment of CHC patients with genotype 2 or 3 infection has a good short-term efficacy, which warrants further investigation.

Key words: Hepatitis C, Sofosbuvir/velpatasvir, Ribavirin, Therapy